At Elanco, we advance our vision of food and companionship enriching life by developing innovative solutions that protect and enhance animal health.
Since 1954, Elanco has been working to empower veterinarians, food producers, and all those concerned with animal health with the tools needed to help animals live healthy lives.
Food and Companionship Enriching Life
We will rigorously innovate to benefit our customers and improve the health of animals.
We will be your advocate and continually earn your trust, improving the health of animals and creating value through innovative products, expertise and service.
Integrity: Do the right thing in the right way.
Respect: Respect for people, our customers and the animals in their care.
Excellence: Be accountable. Continuously improve. Deliver with discipline.
Healthy animals play a critical role in the health of people and our planet. Our business is based on innovative animal health solutions that contribute to healthier animals, and ultimately healthier people and a healthier environment. We believe that starting with animals is the key to solving our global health care, food security, and sustainability challenges.
Elanco combines a holistic world view and decades of experience for a unique perspective in animal health, and its impact on the world. We bring this to life daily, both through the products and services we offer and the initiatives that result from our approach to animal health.
We are proud of our heritage of close customer relationships, scientific rigor, and quality products. It is a history that spans from the development of our first product for livestock in 1953 to today's treatments that address the health needs of our pets. At the same time, we are humbled by the global challenges ahead and and vow to bring needed solutions in the field of animal health.
Elanco has helped shape the lives of animals and their human companions for more than half a century. Explore the timeline below to learn more.
Eli Lilly and Company introduces the first antibiotic exclusively for veterinary use.
New plant and animal science activities are organized and combined into Lilly’s Agricultural and Industrial Sales Division.
The Agricultural and Industrial Sales Division is reorganized, and Elanco Products Company is launched.
Elanco introduces new tools to improve feed efficiency to prevent and control disease, while expanding international operations to include 38 global affiliates and 17 manufacturing plants.
R&D begins to shift away from plant science and towards animal health, with a focus on increasing food quality while reducing production costs.
Elanco Products Company is renamed Elanco Animal Health and focuses solely on producing animal health products.
Elanco launches its companion animal business, bringing in first-class parasiticides technology, and acquires its longtime partner, Ivy Animal Health.
Elanco establishes a partnership with Heifer International to help address the need for safe, affordable, abundant food in developing countries.
Elanco Knowledge Solutions begins providing timely information to help customers make data-driven decisions through analytics and consultation.
Elanco commits to end hunger for 100,000 families globally through a partnership with Heifer International, and expands its European presence through the acquisition of Janssen Animal Health.
Elanco expands its focus on emerging tools like enzymes to unlock nutrients inaccessible in the diets of food animals through acquisition of ChemGen.
Elanco expands its vaccine offerings.
Elanco acquires both Lohmann Animal Health, increasing its poultry and vaccine capabilities, and Novartis Animal Health, increasing its companion animal, livestock, vaccine and aquaculture offerings.
Elanco establishes its 8-point Antibiotic Stewardship Plan to increase responsible use of antibiotics, to reduce the need for shared-class antibiotics, and to replace antibiotics with alternatives.
Elanco expands its U.S. companion animal portfolio by acquiring an innovative platform of vaccines from Boehringer Ingelheim Vetmedica.
Elanco recognized for Best New Products in food and companion animal categories by industry publication Animal Pharm: Clynav, a vaccine for pancreas disease in Atlantic salmon, and Galliprant (grapiprant tablets) for pain control associated with canine osteoarthritis.
Elanco and Heifer International celebrate 10 Years together breaking the Cycle of Hunger for 160,000 Families.
Lilly announced plans to Separate Elanco Animal Health with Initial Public Offering.
Elanco Lists on the New York Stock Exchange (NYSE: ELAN).
Julie Lawless serves as the senior vice president of corporate affairs at Elanco. In this role, she oversees global and regional communications, government affairs, market access, cause and shared value (CSR), as well as the Elanco Pulse Institute Social Listening Center. Lawless has a broad range of corporate affairs experiences from several industries, including corporate communications, issues management and consumer relations within the pet care segment at Mars, as well as internal, regional, and product communications at Nissan North America.
A graduate of the University of Missouri-St. Louis with a bachelor’s degree in communication, Lawless also serves as vice chair for Pet Partners pet therapy organization and communications chairperson for the Health for Animals industry organization.Close Bio
Shawn McKee serves as senior vice president of the U.S. companion animal business for Elanco, where he oversees multiple functional groups including sales, corporate accounts, distribution, strategic accounts and the field technical consultant team. Under his leadership, the team has become one of the largest business units within Elanco. Prior to his current position, McKee was the national sales director for the U.S. Companion Animal Team at Elanco and was responsible for assembling the initial sales organization and creating the distribution network for the new business at the company.
McKee earned his bachelor’s degree in marketing from Penn State University. He currently serves on the board of the American Veterinary Distribution Association.Close Bio
Larbi Van Lier is the senior vice president of Elanco Asia, where he is responsible for operations in the region. In his role, he leads teams charged with expanding Elanco’s global portfolios and developing competitive strategies for the region.
Van Lier joined Elanco as part of the Novartis Animal Health acquisition in 2015, where he was country managing director of Italy. Van Lier brings deep global experience in animal health to this role from his time in key markets that include Italy, Spain, Switzerland and the U.S. While at Novartis, Van Lier held leadership roles that included marketing manager, global marketing director, global category manager and country director for Spain and Portugal.
Van Lier received his bachelor’s degree in marketing from Avans Hogeschool Breda in the Netherlands.Close Bio
Jacques Zimmowitch serves as senior vice president of Global Quality at Elanco. In this role, he brings a passion for ensuring Elanco’s products meet the high standards for quality that help ensure pets and food animals live healthy lives. Previously, Zimmowitch served as vice president of global quality for drug product operations for Americas and Asia, and global computer system operations for Eli Lilly & Company. In this capacity, he was responsible for Good Manufacturing Practices (GMP) compliance for the overall quality of the Lilly U.S. Sales and Marketing affiliates.
Zimmowitch was born and raised in France and holds a master’s degree in DEA biology and physiology from France University of Paris and a Master’s of Business from Essec, France.Close Bio
Rhonda Hoffman is senior vice president and chief marketing officer (CMO) for Elanco Animal Health. In this role, she oversees the global management of Elanco’s marketing strategy, aligning the company vision and core values with effective communication and marketing. Hoffman brings extensive leadership experience in consumer and healthcare marketing, brand strategy and innovation pipeline development to her role. She has spent more than 20 years marketing in the Health, Nutrition and Pet Care industry working for Cardinal Health, Abbott Laboratories, and Procter & Gamble- Pet Health and Nutrition. Previously, Hoffman served as president of Vrios, a management and consulting agency.
Hoffman holds a Master of Business Administration from The Ohio State University. She also serves as an advisor and mentor to Fisher Graduate Women in Business members at The Ohio State University and as president of the Olentangy Booster Association, a nonprofit focused on improving outcomes for student athletes.Close Bio
Fadi Debes joined Elanco in 2018 as senior vice president, Corporate Controller and Global Business Services.
Prior to Elanco, Fadi worked at Eli Lilly and Company starting in 2002 as a financial analyst for the Middle East. He took several roles in finance prior to moving to the U.S. in 2009 as BD director for Emerging Markets. He relocated to Dubai in 2012 heading finance and BD for South Asia, Middle East, Turkey, Africa and Russia-CIS. In 2016, he moved to the UK as CFO for Europe prior to relocating to the U.S. in 2017 where he was most recently a senior director for Lilly Research Laboratories (LRL) covering both Research and the Medicines Development Unit (MDU).
Fadi has a diversified work experience and background. He holds a university degree in specialized mathematics, a bachelor’s degree in civil engineering from Université Saint Joseph in Beirut and a Masters in Management from HEC Paris with Finance as Major.
He initially started his career in construction engineering and project management. Before joining Lilly, he was working in investment banking in Paris.Close Bio
Chris Keeley serves as senior vice president and chief information officer (CIO) of Elanco where he is responsible for leading the company’s global information technology and information security. Keeley brings experience extending across multiple areas of IT and IS to this role, including the development of digital strategy, IT/IS operations and management of global organizations. Prior to joining Elanco, Keeley served as the VP of IT-Products and Engineering Lead at Bayer Crop Science, previously Monsanto, where he oversaw the direction of all technical engineering teams and their delivery of IT products across all Monsanto business functions.
Keeley received his bachelor's degree in physics and geology at Bowdoin College and his master's degree in marine geology and geophysics at Lamont-Doherty Earth Observatory of Columbia University.Close Bio
R. David Hoover is the Chairman of the Elanco Board of Directors.
R. David Hoover retired from Ball Corporation as chief executive officer in 2011 after more than 40 years of service. He retired as chairman of the board of directors in 2013 and continues to serve as a director. After joining Ball Corporation in 1970, Hoover held several leadership positions throughout his tenure, including vice president of finance and administration for both the company’s agricultural systems division and the company’s aerospace systems group; vice president and treasurer; senior vice president and chief financial officer; chief operating officer and more.
Hoover is a member of the boards of Ball Corporation and Edgewell Personal Care Company. Previously he served on the boards of the National Association of Manufacturers, the Irwin Financial Corporation, Qwest International, Inc., and Steelcase, Inc., as well as chair of the board of governors of the Can Manufacturers Institute.
Hoover is a member and past chair of the board of trustees of DePauw University and on the Indiana University Kelley School of Business Dean’s Council. He is also a director of Children’s Hospital Colorado, and a member of the Colorado Forum. He received his bachelor’s degree in economics from DePauw University and his M.B.A. in finance and real estate from Indiana University. Additionally, he completed the advanced management program at Harvard University Graduate School of Business.Close Bio
Jeff Simmons serves as the president and CEO of Elanco Animal Health Incorporated. In this role, Simmons directed the company’s transformation from a primarily US feed additive company to a premier global player with a balanced and diversified business. During Simmons’ tenure Elanco has tripled in size, completed 10 acquisitions and built five new businesses, including a $1 billion companion animal business.
Simmons has held multiple roles with Elanco, including sales and marketing, country director in Brazil, area director for West Europe and executive director for North America and Global Research & Development.
Simmons’ passions for food security and mentoring leaders is evident through his leadership of Hatch™. Hatch provides eggs to food banks in communities across the country, and Edge Mentoring, one of the fastest-growing mentorship organizations in the country. Simmons has also served as board member and chairman of the compensation committee for Chiquita Brands and completed terms as president of the Health for Animals, chairman of the FFA Foundation Board and a board member of Gleaners Food Bank of Indiana. Simmons earned a bachelor’s degree in business from Cornell University.Close Bio
Kapila Kapur Anand has served as a member of the Elanco Board of Directors since September 2018.
Kapila Kapur Anand is a retired KPMG partner who currently serves as a senior adviser to KPMG. During her tenure as a senior partner, Anand held a variety of leadership roles, including serving as an audit signing partner through the evolution of Sarbanes Oxley legislation, an advisory partner building new businesses, an audit committee liaison partner and as a KPMG LLP Board member.
During her career, she served as KPMG’s national partner-in-charge, leading public policy business initiatives responsible for coordinating the U.S. firm’s strategy and response to public policy changes that impact the firm‘s clients. Additionally, she was named the national segment leader for travel, leisure and policy. She has experience building private equity and regulatory businesses and was responsible for architecting and executing strategy in those roles. She was also the architect of KPMG’s inaugural public policy business strategy, which gave her experience across industries with regulatory challenges.
Anand has extensive governance experience through corporate board roles, as well as serving as global chair and lead director of the WomenCorporateDirectors (WCD) organization. She received her Bachelors of Science in accounting and M.B.A. at Michigan State University.Close Bio
Lawrence E. Kurzius has served as a member of the Elanco Board of Directors since September 2018.
Lawrence Kurzius serves as chairman, president and CEO of McCormick & Company. Throughout his tenure, he has served in several leadership positions, including chief operating officer, chief administrative officer, U.S. consumer foods’ president, and president of international business.
Kurzius joined McCormick through the acquisition of Zatarain’s, where he was president and CEO. He also served as a marketing executive with the Quaker Oats Company and Mars Inc.’s Uncle Ben’s Company.
Additionally, he holds positions on the board of directors for the Grocery Manufacturers Association, the National Association of Manufacturers, Greater Baltimore Committee and the National Sporting Library and Museum. Kurzius graduated magna cum laude from Princeton University with a Bachelor of Science in Economics. He is currently a trustee of Jacksonville University.Close Bio
Michael J. Harrington has served as a member of the Elanco Board of Directors since September 2018.
Mike Harrington serves as senior vice president and general counsel for Eli Lilly and Company.
Since joining Lilly, he has served as managing director of the New Zealand affiliate and as associate general counsel for Lilly’s operations in the Asia-Pacific region, as well as other business and legal positions. Previously, Harrington was vice president and general counsel of global pharmaceutical operations. In this capacity, he was responsible for legal issues related to Lilly’s five global business units.
Harrington currently serves as the board chair for the Indiana Repertory Theatre and the co-chair of the Civil Justice Reform Group. He is also a member of the board of trustees and executive committee of Albion College. He earned a bachelor’s degree in English from Albion College and a law degree from the Columbia University School of Law.Close Bio
John Bilbrey has served as a member of the Elanco board of directors since March 2019.
John Bilbrey served as the CEO and president of The Hershey Company until 2017. He also held multiple leadership roles throughout his 14-year tenure with the company, including chief operating officer and executive vice president, president of North America, and president of International Commercial group.
Bilbrey’s past professional experience includes positions as president and CEO of Danone Waters of North America, executive vice president of sales for Mission Foods, and more than 20 years of international consumer sales and marketing experience at Proctor & Gamble. Additionally, he is the owner and operator of Commercial Cattle Operations of Bilbrey Farms and Ranch.
Bilbrey served as non-executive chairman of The Hershey Company until 2018 and an independent director of McCormick & Company, Inc. until 2015. He currently is as an independent director on the board of Colgate-Palmolive Company. Bilbrey earned a bachelor’s degree in psychology from Kansas State University.Close Bio
Deborah T. Kochevar has served as a member of the Elanco board of directors since March 2019.
Deborah Kochevar currently serves as provost and senior vice president ad interim at Tufts University, advancing research and scholarship opportunities across the university.
Dr. Kochevar has extensive experience in veterinary sciences and academia. Before her current role, she served as dean and Henry and Lois Foster professor at the Cummings School of Veterinary Medicine at Tufts University. Dr. Kochevar was also a faculty member at Texas A&M University, Congressional Science fellow to the Senate Labor and Human Resources Committee, and a diplomate and past president of the American College of Veterinary Clinical Pharmacology. She is a former president and chair of the board of directors of the Association of American Veterinary Medical Colleges.
Additionally, Dr. Kochevar has been a director with Charles River Laboratories since 2008 and currently serves on the compensation, nomination and science and technology committees. She earned her undergraduate degree from Rice University, D.V.M from Texas A&M University and a Ph.D. from the University of Texas Southwestern Graduate School of Biomedical Sciences.Close Bio
Kirk McDonald has served as a member of the Elanco board of directors since March 2019.
Kirk McDonald serves as the chief marketing officer of Xandr, AT&T’s advertising company. In his position, McDonald oversees the creation, implementation and execution of Xandr’s marketing strategy.
McDonald is a media and technology veteran with more 25 years of experience working with some of the world’s leading brands and software technology providers. His past roles include president of PubMatric, president of digital at Time Inc., and the chief advertising officer of the Fortune|Money Group. He also worked as senior vice president of network sales for DRIVEpm and Atlas, both key units of Microsoft’s advertising business.
Additionally, McDonald serves on several professional and not-for-profit boards. He was a former advisor on the LUMA Partners board and is currently the chairman of Code Interactive, a non-profit focused on inspiring the next generation of technology leaders from underserved communities. McDonald graduated from The City University of New York where he majored in comparative English literature.Close Bio
Denise Scots-Knights has served as a member of the Elanco board of directors since March 2019.
Denise Scots-Knight serves as the CEO, board member and co-founder of Mereo BioPharma, a specialty biopharmaceutical company that acquires, develops and commercializes therapeutics for the treatment of rare and specialty diseases. Scots-Knight has more than 25 years of experience in the biopharmaceutical industry, working in research and development management and as a venture capitalist. Prior to co-founding Mereo BioPharma, Scots-Knight ran Phase4 Partners, a venture capital business that invested globally in biotechnology companies, having previously led the management buy-out of the business from Nomura. She started her career in research and development management at Amersham and Fisons and as a senior executive at Scientific Generics.
Scots-Knight has served on many United States and European boards including those of Viacell Inc., Idenix Pharmaceuticals, Nabriva Therapeutics, Albireo Pharma and Oncomed Pharma. Additionally, she has been named one of the 15 leading women in European biotech by Labiotech UG. Scots-Knight completed her Ph.D. in biochemistry from Birmingham University.Close Bio
Art A. Garcia has served as a member of the Elanco Board of Directors since May 2019.
Garcia retired as executive vice president and CFO of Ryder System, a $8 billion global leader in transportation and supply chain management solutions, in 2019.As CFO at Ryder System, Inc., Garcia oversaw corporate strategy and corporate development, and led the reengineering of the company’s finance function to drive increasing efficiencies. Garcia was a key member of the Ryder executive team that established a new business model and implemented strategies to revitalize growth and improve profitability. He also managed the financial integration of 12 acquisitions, capturing targeted growth and cost synergy objectives for each.
Garcia sits on the board of ABM Industries, where he is chair of the Audit Committee and a member of the Strategy and Enterprise Risk Committee. A certified public accountant, Garcia began his career with Coopers & Lybrand. He graduated Magna Cum Laude from Florida State University with a bachelor of science degree in accountingClose Bio
Jeff Simmons serves as president and CEO of Elanco Animal Health. A global leader with a 60-year track record of growth, Elanco provides comprehensive products and knowledge services to improve animal health, welfare and food animal production with 125 brands in 90 countries.
As the head of Elanco Animal Health for the past decade, Simmons has directed the company’s transformation from a primarily US feed additive company to a premier global player with a balanced and diversified business. During Simmons’ tenure Elanco has tripled in size, created a unique innovation engine, completed 10 acquisitions and built five new businesses, including a $1 billion companion animal business.
In his nearly 30 years with the company, Simmons has held an array of roles, from sales and marketing, to country director in Brazil, area director for West Europe and executive director for North America and Global Research & Development. In these roles, Simmons gained a new perspective on food, agriculture and companionship that has sparked a deep conviction for finding solutions to achieve global food security through a One Health approach. He’s authored white papers on this subject and helped found the Enough Movement, a 30,000-member global community dedicated to building dialogue and finding practical solutions for a food secure world.
The Elanco team is grounded in delivering a higher purpose: Food and Companionship Enriching Life. The team helps animals and pets live healthy, good quality lives. They support the physical, emotional and social well-being of people through a balanced diet rich in protein and the companionship of pets. And, they preserve the health of the planet by helping farmers raise animals more efficiently.
Simmons brings his passions for food security and enabling leaders to life daily through his pursuits with Hatch™ and Edge Mentoring. As the co-founder of Hatch, Simmons and the team have created a unique, donation-free model to deliver sustained food security through protein and partner value. Today, Hatch provides eggs to food banks in communities across the country. Simmons also founded Edge Mentoring, one of the fastest-growing mentorship organizations in the country, present in over 40 states and reaching into several countries and multiple continents. Edge’s purpose is to equip and accelerate whole-life excellence in the leaders of today and tomorrow.
Simmons has also held a number of leadership positions, including serving as a former board member and chairman of the compensation committee for Chiquita Brands. He has also completed terms as president of the Health for Animals, chairman of the FFA Foundation Board and as a board member of Gleaners Food Bank of Indiana.
For more, you can follow Jeff and Elanco on social media @JeffSimmons2050, @Elanco, or view the ENOUGH report at ENOUGHmovement.com.Close Bio
Ramiro Cabral serves as executive vice president, Elanco International. In this role, he leads Elanco’s international commercial operations.
He was most recently responsible for Elanco’s business in Europe, Middle East and Africa. Previously, he served as Area Director for Western Europe.
Cabral brings a lifetime of global experience across diverse portfolios of animal health to his position. In over twenty years with Elanco, he has been a valuable member of the Elanco team, serving in roles including technical sales at Elanco Argentina, global marketing manager, beef business unit director in the U.S. affiliate and affiliate director at Elanco Canada. Prior to joining Elanco, he worked on his family’s farm and served as a consultant in the veterinary and agribusiness industries.
Cabral earned a Doctorate of Veterinary Medicine degree at UNICEN, Argentina in 1995 and a Master of Business Administration from Purdue University in 2005.Close Bio
Aaron Schacht serves as executive vice president, Innovation, Regulatory, and Business Development at Elanco. In this role, he oversees global R&D, regulatory, business development and nutritional health. With a focus on ideas, products and technologies that address customers’ unmet needs, he applies his passion for scientific discovery to pursue innovative animal health solutions. Schacht and his team collaborate with scientists, animal caretakers, and pharmaceutical product developers to enhance and health and longevity for pets and food animals.
Schacht began his career in R&D more than 25 years ago brings expertise in health care innovation to this position. Prior to this, he served as global brand development leader of pain in Eli Lilly & Company BioMedicines.
In his tenure with Eli Lilly and Company, Schacht has been an integral member of leadership, serving in roles that include senior advisor of strategy & business development for Lilly BioMedicines, executive director of global external R&D at Lilly, executive director of Lilly Research Labs strategy, portfolio management and project management and director of the Innovation Center in the eLilly organization. He began his career at Lilly in 1990 as medicinal chemist working to discover pharmaceuticals to treat cardiovascular disorders.
Schacht studied organic chemistry at the University of Illinois, receiving his bachelor’s degree in 1990.Close Bio
Sarena Lin serves as executive vice president, Elanco USA, Corporate Strategy and Global Marketing. In this role, she merges innovation and technology with diverse talent to help Elanco solve animal health challenges across the U.S. and around the globe. Lin oversees a team tasked with capitalizing on animal health industry growth drivers.
Lin combines expertise in manufacturing and supply-chain driven industries and a passion for growing talent and building effective teams. Prior to joining Elanco in 2018, Lin was president of Cargill’s Global Compound Animal Feed and Nutrition business, where she led more than 11,000 employees across nearly 30 countries. At Cargill, she also served as corporate vice president of strategy and business development. She has also previously served as a partner at McKinsey & Company and was in sales at Procter & Gamble.
Lin earned a Master of Business Administration in strategy from the Yale School of Management, a Master of Arts in international relations from Yale University and a bachelor’s degree in computer science from Harvard University. She previously sat on the Board of Directors of Patterson Companies, Inc.
Lin is active in several community non-profit organizations in Minneapolis and serves on the Board of Directors for the Greater Twin Cities United Way and Perspectives, Inc. In 2014, she was named one of the Top 10 Corporate Women in Minnesota.Close Bio
Michael-Bryant Hicks serves as executive vice president, General Counsel and Corporate Secretary for Elanco. He is responsible for leading the company's legal, ethics and compliance organization and global legal strategy.
Hicks brings extensive corporate legal experience from a variety of industries as well as expertise on advising companies on domestic and international transactions to the Elanco Leadership Team. Prior to joining Elanco, he served as general counsel at Mallinckrodt Pharmaceuticals, where he oversaw all legal functions, including litigation, intellectual property, environmental, regulatory, and mergers and acquisitions. Hicks has also served as senior vice president, general counsel, chief compliance officer and corporate secretary for The Providence Service Corporation, a global provider of a range of healthcare services. Additionally, he has served as assistant general counsel for DaVita and as associate general counsel and head of legal support for the company's Asia and Latin America operations for Beckman Coulter. Hicks also worked in the corporate law practices of two international law firms — Vinson & Elkins LLP and Mayer, Brown, Rowe & Maw LLP.
Hicks received a bachelor’s in psychology from University of North Carolina at Chapel Hill and a Juris Doctor from Yale University.Close Bio
David Kinard serves as executive vice president, Human Resources for Elanco. Kinard brings valuable leadership experience within the pharmaceutical industry and years of managing human resources programs to this position.
Prior to his current role, Kinard served as the vice president of human resources of Lilly International for Eli Lilly & Company where he created valuable human resources programs in diverse geographies and business units. He also served as vice president of human resources for bio-medics and emerging markets, biomedicines and diabetes, Lilly diabetes and global employee relations and Lilly USA. Kinard joined Eli Lilly & Company in 1997 and the first decade of his career included roles as an organizational effectiveness consultant, a HR manager supporting R&D, and director of workforce research and organizational effectiveness. He began his career as an account manager for Walker Customer Satisfaction Measurement, and later as both an organizational development manager and production manager for AlliedSignal.
Kinard holds a bachelor's degree in social science and broadcast communications and a master’s in organizational behavior from Brigham Young University. He also serves on the Board of Directors for Conner Prairie, a living history museum in Fishers, Indiana.Close Bio
David Urbanek serves as executive vice president, Manufacturing and Quality for Elanco. He and his team have led the company in rightsizing Elanco’s manufacturing footprint and centralizing resources. Urbanek brings over 30 years of experience in key roles within Eli Lilly & Company and Elanco where he has led pharmaceutical manufacturing in both drug product and bulk manufacturing.
Urbanek joined Elanco as vice president of animal health manufacturing in February 2017. Before joining Elanco, he held leadership roles in Lilly’s manufacturing division, including senior director of emerging markets manufacturing, senior director of global diabetes manufacturing and senior director of external drug products operations. Prior to those roles, Urbanek was the general manager of operations for Lilly divisions in Ireland, England, Germany and the U.S.
Urbanek received his bachelor’s degree in mechanical engineering from the Rose-Hulman Institute of Technology and obtained his Master of Business Administration from Indiana University.Close Bio
Todd Young serves as an executive vice president and chief financial officer (CFO) at Elanco Animal Health Incorporated. In this role, he is responsible for leading all of the company’s financial operations.
Young brings significant financial leadership experience in pharmaceutical and healthcare, as well as a focus on strategic and commercial decision-making to his position. Prior to joining Elanco, Young served as the chief financial officer at ACADIA Pharmaceuticals Inc, where he oversaw the company’s financial functions, including accounting and financial planning and analysis. He also had responsibility for the information technology and facility groups. Young has also served as senior vice president and treasurer at Baxalta, a bio-pharmaceutical leader in hematology, immunology and oncology that was created as a tax-free spin-off from Baxter International. He has also served as corporate vice president and treasurer of Baxter. At Baxter, Young also served in roles including vice president of international finance, vice president of global financial planning and analysis, vice president of finance of Asia Pacific, and assistant treasurer. He started at Baxter in the tax group.
Young received his bachelor’s degree in economics from Grinnell College and a Juris Doctor from the University of Michigan.Close Bio
In line with the values that guide our company, Elanco is committed to earning the trust and confidence of all of our stakeholders. We embrace the principles of good corporate governance and implement them through strong and diverse membership on our Board of Directors and a commitment to maintaining the highest of ethical standards. We will do this by remaining a leader in good corporate governance and providing clear, transparent and timely communication about our performance.
By selecting the links below, you can access information about our corporate governance principles, other key corporate governance information and our SEC filings.
|Member||Board ofDirectors||AuditCommittee||CompensationCommittee||Nominating andCorporateGovernanceCommittee||Finance
|R. David Hoover||Chair||Member||-||Chair||-|
|Jeffrey N. Simmons||Member||-||-||-||Member|
|Kapila Kapur Anand C.P.A||Member||Chair||-||-||Member|
|Michael J. Harrington||Member||-||-||-||Member|
|Lawrence E. Kurzius||Member||-||Chair||-||Member|
|Deborah T. Kochevar||Member||-||Member||Member||-|